ENvarsus for Impaired Glucose Tolerance Post REnal transplAnT
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Our hypothesis is that switching from the current standard of care twice daily Adoport
(Tacrolimus) to once daily Envarsus (tacrolimus) in patients who have impaired glucose
tolerance post-transplant will lead to an improvement in their glucose tolerance, and may
reduce the subsequent incidence of PTDM.